Physician profile
Erin Davlin
NPI 1104895036
$4,007.83
in general payments reported to CMS, 2019-2025
41 companies · $61.00 in 2025
The $61.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $384 · 2021: $829 · 2022: $900 · 2023: $789 · 2024: $217 · 2025: $61.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $630.33 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $596.11 | 2019-2023 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $342.01 | 2019-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $256.50 | 2019-2022 | |
| Amgen INC. | $237.60 | 2019-2024 | Repatha, Otezla |
| Boston Scientific Corporation | $230.17 | 2019-2021 | |
| Pfizer INC. | $173.41 | 2019-2023 | |
| Glaxosmithkline, LLC. | $133.77 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $133.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $99.93 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $98.06 | 2019-2023 | Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.33 | 2020-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.74 | 2019-2023 | Xifaxan |
| Astellas Pharma US INC | $69.99 | 2021-2023 | Myrbetriq |
| Corium, LLC | $68.08 | 2022-2023 | Azstarys |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Davlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.